MedStar Georgetown and MedStar Health Institute are partnering with Johns Hopkins to test whether antibody rich plasma can treat or even prevent COVID from happening. They are looking for people who have been exposed to someone with the virus in the last 3 days or tested positive for COVID within the last 5 days and still have symptoms. This could be one of the best shots of ending this pandemic. Go to covidplasmatrial.org or call 888-506-1199 to enroll.
Who: People who either:
A.Were tested for Covid-19 no more than 5 days ago and were positively diagnosed, who still have symptoms but haven’t been hospitalized. Study details are here.
B.Were in close contact with someone who has Covid-19 no more than 3 days ago, who don’t have any symptoms. Study details are here.
What: This trial will help determine whether antibodies from people who have recovered from Covid-19 can help people who have either been recently exposed, or who have been recently diagnosed and have symptoms, avoid getting very sick. While other antibody trials are underway for people who have needed hospitalization, this set of two studies seeks to determine whether giving people antibodies earlier in the illness is effective at treating early-stage coronavirus and in preventing those exposed to it from catching the disease.
Will participants be compensated? Yes. More details are available once they have contacted the investigators via the website or phone number below.
How to enroll and when: Enrolling now. Those who have been recently exposed, or are newly diagnosed and have symptoms, can contact Johns Hopkins at 888-506-1199 or www.covidplasmatrial.org to take the enrollment questionnaire – if too many days pass, they may not qualify to participate. This study is entirely voluntary, and participants will be compensated.
Why does this trial matter? This is the first U.S. multi-center, double-blind, randomized clinical trial to assess the effectiveness of convalescent blood plasma as an outpatient therapy. Antibodies are one of the best options being tested for treatment and prevention. If this option is deemed effective, it would be one of the lower-cost options for treating and/or preventing coronavirus illness worldwide.